Systemic Inflammatory Response Syndrome in Tissue-Type Plasminogen Activator–Treated Patients is Associated With Worse Short-term Functional Outcome | Zendy

Amelia K. Boehme | Zendy; Niren Kapoor | Zendy; Karen C. Albright | Zendy; Michael Lyerly | Zendy; Pawan Rawal | Zendy; Reza Bavarsad Shahripour | Zendy; Muhammad Alvi | Zendy; James T Houston | Zendy; April Sisson | Zendy; T. Mark Beasley | Zendy; Anne W. Alexandrov | Zendy; Andrei V. Alexandrov | Zendy; David W. Miller | Zendy

Open Access

Systemic Inflammatory Response Syndrome in Tissue-Type Plasminogen Activator–Treated Patients is Associated With Worse Short-term Functional Outcome

Author(s) -

Amelia K. Boehme,

Niren Kapoor,

Karen C. Albright,

Michael Lyerly,

Pawan Rawal,

Reza Bavarsad Shahripour,

Muhammad Alvi,

James T Houston,

April Sisson,

T. Mark Beasley,

Anne W. Alexandrov,

Andrei V. Alexandrov,

David W. Miller

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.113.001371

Subject(s) - medicine , systemic inflammatory response syndrome , odds ratio , plasminogen activator , confidence interval , gastroenterology , acute coronary syndrome , tissue plasminogen activator , inflammation , surgery , myocardial infarction , sepsis

Systemic inflammatory response syndrome (SIRS) is a generalized inflammatory state. The primary goal of the study was to determine whether differences exist in outcomes in SIRS and non-SIRS intravenous tissue-type plasminogen activator-treated patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research